TABLE 3.
Efficacy of sordarin derivatives against systemic aspergillosis in mice
| Compounda (MIC [μg/ml]) | Dose (mg/kg) | No. of survivors/ total no. of mice | Survival (days)b
|
||
|---|---|---|---|---|---|
| Mean ± SE | Median | Range | |||
| Control | 1 /10 | 4.7 ± 1.12 | 3.0 | 3–15 | |
| GM237354 (64) | 10 | 0 /10 | 4.0 ± 0.21 | 4.0 | 3–5 |
| 20 | 3 /10 | 8.2 ± 1.47 | 6.0 | 3–15 | |
| 40 | 0 /10 | 4.9 ± 0.55 | 4.0 | 3–8 | |
a
GM237354 was administered subcutaneously every 8 h (t.i.d.) for five consecutive days.
b
P values, comparing survival in treated and control groups by log rank test, were 0.82, 0.04, and 0.49 for 10, 20, and 40 mg/kg, respectively.